Retinal Vein Occlusion Treatment Market on Track for Strong Growth, Estimated to Grow at 7% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Retinal Vein Occlusion Treatment Market Through 2025?
The market size for treatment of retinal vein occlusion has seen significant advancement in the recent years. A rise from $2.26 billion is projected in 2024 to an estimated $2.43 billion in 2025 with a compound annual growth rate (CAGR) of 7.3%. The historical growth has been largely due to the utilisation of combined therapies which address varied elements of the disease's pathophysiology, the surge in incidents of diabetes and hypertension and greater availability of healthcare services along with specialised retinal care. It's also credited to the successful clinical trials showcasing the effectiveness of new treatment methods as well as the establishment of anti-VEGF therapies.

What's the Projected Size of the Global Retinal Vein Occlusion Treatment Market by 2029?
In the coming years, the retinal vein occlusion treatment market is predicted to undergo massive expansion. Its size will escalate to $3.18 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. This advancement over the anticipated period is due to factors such as cost-effectiveness, favorable reimbursement policies, the popularity of non-invasive treatments among patients, an increase in worldwide healthcare expenditure, and a growing older population. Plus, the invention of novel drugs and therapies will also drive growth. Key market trends to be watched during the forecast period are improvements in gene therapy, the use of nanotech in drug delivery, the application of artificial intelligence (AI) in diagnostics, telemedicine alongside remote monitoring, and the creation of technologies focused on patient needs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-treatment-global-market-report

Top Growth Drivers in the Retinal Vein Occlusion Treatment Industry: What's Accelerating the Market?
The escalating instances of eye-related disorders are projected to fuel the expansion of the retinal vein occlusion treatment market. These eye conditions encompass any disease or disorder that impacts eyesight or the eyes themselves ranging from trivial irritations and infections to more grave conditions like glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The heightened instances of these eye conditions are linked to elements like advancing age populations and an increased occurrence of diseases like diabetes and hypertension. The objective of treatment for retinal vein occlusion is to reinstate blood circulation and minimize inflammation to avert vision loss and manage complications that come with this eye condition. For example, per the Centers for Disease Control and Prevention's report in January 2024, a US-based organization driven by science and data that safeguards public health, over 3.4 million Americans aged 40 years and older either had impaired vision or were completely blind, a number expected to double by 2030. Hence, the escalating instances of eye conditions are fostering the expansion of the retinal vein occlusion treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp

What Trends Will Shape the Retinal Vein Occlusion Treatment Market Through 2029 and Beyond?
In an effort to improve patient accessibility and expand treatment choices, top-tier companies in the retinal vein occlusion treatment industry are turning their attention to the creation of ground-breaking products like interchangeable biosimilars. Interchangeable biosimilars serve as reliable substitutes for currently existing reference biologics, providing robust management of inflammation and fluid leakage. For instance, in May 2024, Biocon Biologics Limited - a renowned biosimilar producer from India, earned the green light from the US Food and Drug Administration for its product Yesafili (aflibercept-jbvf), an interchangeable biosimilar of EYLEA (aflibercept). This product is an inhibitor of vascular endothelial growth factor (VEGF) and is effective in treating diverse eye-related conditions such as neovascular age-related macular degeneration (wet AMD), retinal vein occlusion induced macular edema (branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularization (myopic CNV).

What Are the Main Segments in the Retinal Vein Occlusion Treatment Market?
The retinal vein occlusion treatment market covered in this report is segmented -

1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)
2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography
3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments
4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users

Subsegments:
1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO
2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18453&type=smp

Which Top Companies are Driving Growth in the Retinal Vein Occlusion Treatment Market?
Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.

Which Regions Will Dominate the Retinal Vein Occlusion Treatment Market Through 2029?
North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.